The global pharmaceutical landscape in 2026 is no longer defined by the linear “West-innovates, East-manufactures” paradigm that dominated the early […]

A deep-dive for pharma/biotech IP teams, R&D leads, and institutional investors on PBM market power, formulary mechanics, IP asset valuation,

Why Litigation Data Outperforms Every Other LOE Signal Patent expiration dates are public. Orange Book listings are public. FDA tentative

Track Any Drug Pipeline Through Patent Filings: The Pharma Analyst’s Intelligence Playbook Why Patent Filings Beat Every Other Intelligence Source

The pharmaceutical market in the United States functions as a regulated trade-off between the necessity of innovation and the demand

Why Patent Data Is the Most Underused BD Tool in CDMO Sales Most CDMOs sell on the same four claims:

Global Key Takeaways The FDA’s Orange Book is not a passive regulatory registry. It is the legal terrain on which

Executive Summary: The Economics of Loss of Exclusivity In the pharmaceutical sector, the transition from patent exclusivity to generic or

A single ClinicalTrials.gov entry can redirect millions in legal fees. When a specialty pharma company quietly posts a Phase II